Your browser doesn't support javascript.
loading
Ancestral SARS-CoV-2 driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth
Suprit Deshpande; Mohammed Yousuf Ansari; Jyoti Sutar; Payel Das; Nitin Hingankar; Sohini Mukherjee; Priyanka Jayal; Savita Singh; Anbalagan Anantharaj; Janmejay Singh; Souvick Chattopadhyay; Sreevatsan Raghavan; Mudita Gosain; Supriya Chauhan; Shweta Shrivas; Chaman Prasad; Sangeeta Chauhan; Neha Sharma; Pradipta Jana; Ramachandran Thiruvengadam; Pallavi Kshetrapal; Nitya Wadhwa; Bhabatosh Das; Gaurav Batra; Guruprasad R. Medigeshi; Devin Sok; Shinjini Bhatnagar; Pramod Garg; Jayanta Bhattacharya.
Afiliação
  • Suprit Deshpande; Translational Health Science & Technology Institute
  • Mohammed Yousuf Ansari; Translational Health Science and Technology Institute
  • Jyoti Sutar; Translational Health Science and Technology Institute
  • Payel Das; Translational Health Science and Technology Institute
  • Nitin Hingankar; Translational Health Science and Technology Institute
  • Sohini Mukherjee; International AIDS Vaccine Initiative
  • Priyanka Jayal; Translational Health Science and Technology Institute
  • Savita Singh; Translational Health Science and Technology Institute
  • Anbalagan Anantharaj; Translational Health Science and Technology Institute
  • Janmejay Singh; Translational Health Science and Technology Institute
  • Souvick Chattopadhyay; Translational Health Science and Technology Institute
  • Sreevatsan Raghavan; Translational Health Science and Technology Institute
  • Mudita Gosain; Translational Health Science and Technology Institute
  • Supriya Chauhan; Translational Health Science and Technology Institute
  • Shweta Shrivas; Translational Health Science and Technology Institute
  • Chaman Prasad; Translational Health Science and Technology Institute
  • Sangeeta Chauhan; Translational Health Science and Technology Institute
  • Neha Sharma; Translational Health Science and Technology Institute
  • Pradipta Jana; Translational Health Science and Technology Institute
  • Ramachandran Thiruvengadam; Translational Health Science and Technology Institute
  • Pallavi Kshetrapal; Translational Health Science and Technology Institute
  • Nitya Wadhwa; Translational Health Science and Technology Institute
  • Bhabatosh Das; Translational Health Science and Technology Institute
  • Gaurav Batra; Translational Health Science and Technology Institute
  • Guruprasad R. Medigeshi; Translational Health Science and Technology Institute
  • Devin Sok; International AIDS Vaccine Initiative
  • Shinjini Bhatnagar; Translational Health Science and Technology Institute
  • Pramod Garg; Translational Health Science and Technology Institute
  • Jayanta Bhattacharya; Translational Health Science & Technology Institute
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-512979
ABSTRACT
Understanding the quality of immune repertoire triggered during natural infection can provide vital clues that form the basis for development of humoral immune response in some individuals capable of broadly neutralizing pan SARS-CoV-2 variants. We assessed the diversity of neutralizing antibody responses developed in an unvaccinated individual infected with ancestral SARS-CoV-2 by examining the ability of the distinct B cell germline-derived monoclonal antibodies (mAbs) in neutralizing known and currently circulating Omicron variants by pseudovirus and authentic virus neutralization assays. The ability of the antibodies developed post vaccination in neutralizing Omicron variants was compared to that obtained at baseline of the same individual and to those obtained from Omicron breakthrough infected individuals by pseudovirus neutralization assay. Broadly SARS-CoV-2 neutralizing mAbs representing unique B cell lineages with non-overlapping epitope specificities isolated from a single donor varied in their ability to neutralize Omicron variants. Plasma antibodies developed post vaccination from this individual demonstrated neutralization of Omicron BA.1, BA.2 and BA.4 with increased magnitude and found to be comparable with those obtained from other vaccinated individuals who were infected with ancestral SARS-CoV-2. Development of B cell repertoire capable of producing antibodies with distinct affinity and specificities for the antigen immediately after infection capable of eliciting broadly neutralizing antibodies offers highest probability in protecting against evolving SARS-CoV-2 variants. ImportanceDevelopment of robust neutralizing antibodies in SARS-CoV-2 convalescent individuals is known, however varies at population level. We isolated monoclonal antibodies from an individual infected with ancestral SARS-CoV-2 in early 2020 that not only varied in their B cell lineage origin but also varied in their capability and potency to neutralize all the known VOC and currently circulating Omicron variants. This indicated establishment of unique lineages that contributed in forming B cell repertoire in this particular individual immediately following infection giving rise to diverse antibody responses that could compensate each other in providing broadly neutralizing polyclonal antibody response. Individuals who were able to produce such potent polyclonal antibody responses after infection have a higher chance of being protected from evolving SARS-CoV-2 variants.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...